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Abstract: Development of effective antibacterial agents for the treatment of infections 
caused by Gram-positive bacteria resistant to existing antibiotics, such as methicillin-resistant 
Staphylococcus aureus (MRSA), is an area of intensive research. In this work, the antibacterial 
efficacy of two antimicrobial peptides derived from plectasin, AP114 and AP138, used alone and 
in combination with monolaurin-lipid nanocapsules (ML-LNCs) was evaluated. Several inter-
esting findings emerged from the present study. First, ML-LNCs and both plectasin derivatives 
showed potent activity against all 14 tested strains of S. aureus, independent of their resistance 
phenotype. Both peptides displayed a considerable adsorption (33%–62%) onto ML-LNCs 
without having an important impact on the particle properties such as size. The combinations 
of peptide with ML-LNC displayed synergistic effect against S. aureus, as confirmed by two 
methods: checkerboard and time-kill assays. This synergistic interaction enables a dose reduc-
tion and consequently decreases the risk of toxicity and has the potential of minimizing the 
development of resistance. Together, these results suggest that ML-LNCs loaded with a plectasin 
derivative may be a very promising drug delivery system for further development as a novel 
antibacterial agent against S. aureus, including MRSA.
Keywords: nanoparticles, antimicrobial peptides, glycerol monolaurate, synergy, antibiotic 
resistance, MRSA, methicillin-resistant Staphylococcus aureus
Introduction
Staphylococcus aureus is a Gram-positive bacterium with spherical shape (cocci) 
that grows in clusters resembling grapes. This facultative anaerobe can frequently be 
found in the nose, respiratory tract, and on the skin. Although S. aureus is usually not 
pathogenic, it can cause skin infections such as abscesses or scalded skin syndrome, 
pyogenic infections (eg, endocarditis, septic arthritis), respiratory infections such as 
sinusitis or hospital-acquired pneumonia, toxic shock syndrome, and food poisoning.1 
The emergence of S. aureus strains such as methicillin-resistant S. aureus (MRSA) 
that have developed multiresistance to beta-lactam antibiotics including the penicillins 
(methicillin, nafcillin, and so on) and the cephalosporins is a worldwide problem in 
clinical medicine.2 Strains unable to resist these antibiotics are referred to as methicillin-
susceptible S. aureus (MSSA). Although MRSA strains are not necessarily more viru-
lent than MSSA strains, some MRSA strains contain factors or genetic backgrounds 
that may enhance their virulence or may enable them to cause particular clinical 
syndromes.3 Moreover, the resistance makes the MRSA infections more difficult to 
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treat with standard antibiotics and therefore more dangerous.4 
MRSA infections are particularly problematic in places such 
as hospitals and nursing homes, where patients with open 
wounds, invasive devices, and weakened immune systems 
are at greater risk of infection than the general public.5 Hence, 
there is an urgent need to develop new antibacterial agents 
for the prevention and treatment of the infections caused by 
S. aureus, particularly by the MRSA strains.
Plectasin is a cationic antimicrobial peptide, which 
belongs to the class called defensins. It was obtained from 
the saprophytic ascomycete Pseudoplectania nigrella. It is 
composed of 40 amino acids and exhibits a potent activity 
against Gram-positive bacteria in vitro and in vivo.6–8 AP114 
(formerly known as NZ2114) is a plectasin derivative with 
an improved activity against staphylococci and streptococci, 
including strains resistant to standard antibiotics.6,7,9–12 AP138 
is the product of an extensive lead optimization program 
based on a set of in silico generated plectasin variants.13
In most cases, the single best antimicrobial agent should 
be selected for use because this minimizes side effects. How-
ever, there are several instances in which two or more drugs 
are commonly given, such as treatment of serious infections 
before the identity of the organism is known or achievement 
of a synergistic inhibitory effect against certain organisms. 
Using drug combinations also offers the advantage of preven-
tion of the emergence of drug-resistant organisms – if bacteria 
become resistant to one drug, the second drug will kill them 
thereby preventing the emergence of resistant strains.1
Monolaurin, also known as glycerol monolaurate or 
1-lauroyl-glycerol, is a monoester formed from lauric acid 
and glycerol. This compound exhibits a potent activity against 
Gram-positive cocci and Bacillus anthracis.14 Monolaurin 
has been proven to be effective against both susceptible and 
resistant strains of S. aureus.15 Glycerol monolaurate is gen-
erally recognized as safe for human use by Food and Drug 
Administration, and this compound is commonly used in 
the cosmetic and food industries.16,17 Unlike most antibiotics 
that have single targets for antibacterial activity, monolaurin 
appears to target nonspecifically many signal transduction 
systems present at bacterial surface through interactions with 
plasma membranes.14 The main disadvantage of monolaurin 
is poor solubility in water, which may cause problems with 
its administration via different routes. One of the strategies 
to resolve the problem of poor solubility in water is by using 
nanocarriers, such as lipid nanocapsules (LNCs).18
LNCs are biomimetic nanocarriers obtained by the phase 
inversion temperature method.19 LNCs have been widely 
studied as carriers for lipophilic compounds.20,21 Our recent 
study showed that LNCs are capable of effectively adsorbing 
peptides, including AP114.22 Recently, we proposed using 
fatty acids or monoglycerides as cosurfactants to obtain LNCs 
with antibacterial properties.18 Monolaurin proved to be the 
most promising cosurfactant among all tested fatty acids and 
monoglycerides. Monolaurin-LNCs (ML-LNCs) exhibited 
the lowest minimum inhibitory concentration (MIC) or mini-
mum bactericidal concentration (MBC) against two strains 
of S. aureus: one MSSA and one MRSA. Moreover, they 
showed the lowest toxicity among the tested LNCs, with the 
bactericidal concentration being 32- or 64-fold higher than 
the hemolytic concentration.18
The aim of the present work was to study the antibacte-
rial activity of plectasin derivatives, AP114 and AP138, 
against seven MSSA and seven MRSA strains and to further 
investigate the antibacterial activity of ML-LNCs. To date, 
no studies have been performed to analyze the interactions 
between the peptides and ML-LNCs. Therefore, another pur-
pose of this paper was to evaluate the adsorption of plectasin 
derivatives onto these nanocarriers. Because ML-LNCs have 
antibacterial properties, it is very important to investigate 
their influence on the activity of the peptide. Hence, the last 
important aim of this work was to investigate in vitro inter-
actions between ML-LNCs and plectasin derivatives using 
time-kill assay and checkerboard method.
Materials and methods
Materials
Antimicrobial peptide AP114 was synthesized and pro-
vided by Adenium Biotech (Denmark) and AP138 was 
synthesized and provided by PolyPeptide Laboratories 
(Limhamn, Sweden). Monolaurin was purchased from 
Sigma Aldrich (France). Labrafac® WL1349 (caprylic/capric 
acid triglycerides) was kindly provided by Gattefossé S.A. 
(Saint-Priest, France). Lipoid® S75–3 (soybean lecithin) was 
kindly provided by Lipoïd Gmbh (Ludwigshafen, Germany). 
Solutol® HS15 (macrogol 15 hydroxystearate, polyoxyl 15 
hydroxystearate; CAS number: 70,142–34-6; molecular 
weight 963.24 g/mol; HLB 14–16) was kindly provided 
by BASF (Ludwigshafen, Germany). Brain–heart infusion 
(BHI) broth was obtained from bioMérieux (France). Plates 
with Columbia agar supplemented with sheep blood were 
purchased from Oxoïd (France). All other chemicals and 
solvents were of analytical grade.
Preparation of lNcs
ML-LNCs were prepared at a concentration of 200 mg/mL 
as described by Umerska et al.18 The components of the 
LNCs (polyoxyl 15 hydroxystearate 0.77 g, triglycerides 
0.93 g, and monolaurin 0.3 g) and NaCl (0.089 g) were 
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weighed, mixed with 3 mL of water, and heated to 60°C 
and then cooled to 20°C. The sample was treated with 
three heating–cooling cycles; during the last cooling cycle, 
at the phase inversion temperature (37°C), the system was 
diluted with water to a final volume of 10 mL (Figure 1). 
The LNC dispersions were diluted with an aqueous solution 
of the plectasin derivative or water (control) and incubated 
at 37°C for 2 hours (sufficient for peptide molecules to 
achieve a dynamic equilibrium between the LNCs and the 
surrounding medium).
characterization of lNcs
The Z-average particle diameter (“cumulants mean”) and 
the polydispersity index of the LNCs were determined by 
dynamic light scattering (DLS) using 173 degree-angle 
backscatter detection. DLS measurements were con-
ducted on a Zetasizer nano series Nano-ZS fitted with a 
633 nm laser (Malvern Instruments, UK) as described 
previously.20
rheological properties of Ml-lNcs
Non-steady flow properties of the aliquots of ML-LNCs 
(concentration of 200 mg/mL) were studied using a 
Kinexus® rheometer (Malvern Instruments S.A., UK), with 
cone plate geometry (diameter 40 mm, angle: 2°) and with 
controlled shear rates ranging from 10 to 1,000 s-1 at 37°C 
(2 minute of equilibration time before the measurement). 
The profiles of shear viscosity versus shear rate were 
registered in triplicate. Viscosity results were expressed 
as a mean.
Peptide-loading studies
separation of nonadsorbed peptide and extraction 
of adsorbed peptide
Nonadsorbed peptide was separated from the LNCs using 
a combined ultrafiltration–centrifugation technique as 
described previously.22
The adsorption efficiency (AE) and drug loading (DL) 
were calculated using the following equations:
 AE = [(A - B)/A] * 100% (1)
where A is the total amount (mass) of the peptide (AP114 or 
AP138), and B is the mass of the nonadsorbed peptide.
 DL = [(A - B)/C] * 100% (2)
where C is the total weight of all components of the nanocar-
riers (the associated peptide and the mass of surfactants and 
oil used for the preparation of the LNCs).
Quantification of peptides by high-performance 
liquid chromatography
The AP114 and AP138 contents were analyzed using a 
high-performance liquid chromatography system described 
previously.22 Briefly, standard solutions of the APIs 
(0.1–1,000 µg/mL) were prepared in deionized water, 
and 20 µL of the standard or sample was injected into 
the SymmetryShield™ RP
18
 5 µm 4.6×250 mm column 
(Waters, USA). A flow rate of 1.0 mL/min was employed 
using mobile phase A composed of 0.1% trifluoroacetic 
acid (TFA) in water and mobile phase B composed of 0.1% 
TFA in acetonitrile. A linear gradient was run: 20% B for 
25 minutes, 45% B for 0.1 minute, 100% B for 4.9 minutes, 
20% B for 0.1 minute, and 20% B for 14.9 minutes. The 
API peaks had retention times of ~12 minutes for AP114 
and 13 minutes for AP138, respectively. The UV detection 
was performed at 200 nm. Data collection and integration 
were accomplished using Empower®3 software.
The method showed good linearity for both molecules, 
AP114 and AP138 (R20.9999). The quantification limits 
were 0.5 µg/mL for AP114 and 1 µg/mL for AP138, whereas 
the detection limits were 0.25 and 0.5 µg/mL for AP114 
and AP138, respectively. More than 90% of peptides were 
recovered each time.
Figure 1 schematic representation of preparation of Ml-lNcs and peptide-loaded Ml-lNcs.
Abbreviation: Ml-lNcs, monolaurin-lipid nanocapsules.
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Microorganisms
The strains used in this study were seven methicillin-resistant 
clinical isolates of S. aureus, six methicillin-susceptible 
clinical isolates, and one reference strain of S. aureus 
(ATCC 25923).
Preparation of inoculum
One to two colonies were taken directly from the Columbia 
agar plate into 2 mL of 0.85% NaCl solution, and the 
density of the microorganism suspension was adjusted to 
1.1 McFarland. The bacterial suspensions were then further 
diluted 100 times with BHI medium.
MIc determination
MIC was determined via a broth microdilution method, as 
described previously18,23 with slight modifications. Serial 
two-fold dilutions of the samples in BHI were prepared in 
order to obtain the desired concentration range. An amount 
of 50 µL of a bacterial suspension in BHI broth was added 
into each well of a sterile 96-well plate already containing 
50 µL of the tested sample or control. The positive control 
wells contained BHI and the bacterial suspension without 
the tested sample, whereas the negative control wells 
contained BHI and the tested sample without the bacterial 
suspension. The samples were incubated for 24 hours at 
37°C. The MIC was the lowest concentration that com-
pletely inhibited the growth of the bacteria as detected by 
the unaided eye.
checkerboard titration
Combinations of ML-LNCs and plectasin derivatives were 
tested via a checkerboard titration method. Two-fold dilu-
tions of ML-LNCs and peptide were prepared before mixing. 
The concentration range of each antimicrobial agent in com-
bination ranged from 1/32× MIC to 4× MIC. The fractional 
inhibitory concentration (FIC) index was calculated using 
the following equation:
 
FIC =
MIC
MIC
MIC
MIC
A B
A
B A
B
+
 
where MIC
A
 is the MIC of the compound A alone, MIC
A/B 
is the MIC of compound A in combination, and MIC
B
 and 
MIC
B/A 
are the MIC of the compound B alone and in com-
bination, respectively.
Synergy was defined as an FIC index of 0.5, additivity/
indifference as an FIC index of 5 but of 4. Antagonism 
was defined as an FIC index of 4.24
Time-kill assay
Samples were diluted with BHI medium to a volume of 
1.98 mL, and 20 µL of bacterial suspension (see “Preparation 
of inoculum” section) was added into each tube. Samples 
were then incubated at 37°C. An amount of 100 µL was 
withdrawn from each tube after 0, 3, 6, 18, and 24 hours and 
serial 100-fold dilutions were prepared in distilled water. 
A total of 100 µL of the diluted and/or undiluted sample were 
delivered onto the surface of the agar, spread, and allowed to 
be absorbed into the agar. After overnight incubation of the 
agar plates at 37°C, the colonies were counted.
Transmission electron microscopy
Twenty microliters of inoculum was added to 0.98 mL of 
BHI broth and incubated for 10 hours at 37°C. One milliliter 
of sample dispersed in BHI or BHI on its own (control) was 
then added followed by incubation for 1 hour. The bacteria 
were collected by centrifugation (10,000× g, 5 minutes) 
and suspended in 0.1 M phosphate-buffered saline (PBS) 
(pH =7.4). After centrifugation, the bacteria were fixed with 
2% paraformaldehyde and 2% glutaraldehyde in 0.1 M PBS 
(pH =7.4) and left overnight under vacuum. The bacteria were 
centrifuged, suspended in PBS, centrifuged, resuspended in 
water, centrifuged, resuspended in 1% osmium tetroxide 
in water, and incubated for 1 hour at room temperature. 
Samples were washed and dehydrated with graded etha-
nol solutions (twice with deionized water for 10 minutes, 
50% ethanol for 20 minutes, 70% ethanol for 20 minutes, 
95% ethanol for 20 minutes, and three times with 100% 
ethanol for 30 minutes). Samples were then embedded in 
Epon 812 resin, which was then left to polymerize for a 
few days. Thin slices (~60 nm) were cut from each sample 
using Leica UC7 ultramicrotome and deposited onto cop-
per grids. The samples were stained with 3% uranyl acetate 
in 50% ethanol for 15 minutes and washed with deionized 
water. The samples were examined using JEOL JEM-1400 
electron microscope.
statistical analysis
The statistical significance of the differences between 
samples was determined using one-way analysis of variance. 
Differences were considered significant at P0.05.
Results and discussion
Properties of Ml-lNcs and peptide-
loaded Ml-lNcs
LNCs are composed of an oily core of capric/caprylic acid 
triglycerides that is surrounded by a shelf composed of a 
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hydrophilic surfactant, for example, macrogol 15 hydroxy-
stearate. Although it is possible to obtain LNCs using solely 
macrogol 15 hydroxystearate as a surfactant, usually a cosur-
factant is used to increase the LNC stability and decrease their 
size. The most common cosurfactant is lecithin.18–20,25 The 
macrogol 15 hydroxystearate/triglycerides mass mixing ratio 
(MMR) of 0.82 was selected as this is the ratio present in the 
most commonly described LNCs.18,21 A previous study has 
shown that it is the monolaurin that makes the LNCs active 
against Gram-positive bacteria. It is important to use a high 
concentration of monolaurin to reduce the amount of the 
nanocarrier required to achieve a desired effect. LNCs com-
posed of monolaurin (15.0%), macrogol 15 hydroxystearate 
(38.4%), and triglycerides (46.6%) were characterized by a 
hydrodynamic diameter of 36±0.3 nm and homogeneous 
size distribution (polydispersity index below 0.1). The zeta 
potential of ML-LNCs was close to neutral (-4.77±2.19).18 
This is not surprising, as ML-LNCs do not contain ioniz-
able molecules. The incorporation of monolaurin resulted 
in an important decrease in phase inversion temperature 
from 80 to 85°C (LNCs composed solely of macrogol 15 
hydroxystearate and triglycerides or lecithin-LNCs) to 37°C 
(ML-LNCs). The concentration of surfactants and oil in ML-
LNCs at 200 mg/mL was sufficiently high for the system to 
undergo phase inversion on heating. Because monolaurin is 
not soluble in water, the use of LNCs offers the advantage of 
obtaining pharmaceutically acceptable dosage form without 
using organic solvents or cosolvents.
The shape of the flow curves (Figure 2) indicates that 
ML-LNC dispersion at a concentration of 200 mg/mL 
exhibits a shear thickening flow. In this non-Newtonian flow 
phenomenon, shear viscosity decreases (about 10-fold) as the 
shear rate is increased (about 100-fold). The non-Newtonian 
behavior can be observed in concentrated particle systems 
because of asymmetrical microstructure caused by particle–
particle flow field interactions.26
In addition to covalent attachment and encapsulation 
within the nanocarrier, surface adsorption is one approach for 
incorporating drug molecules into drug delivery systems.27 
Due to their small size and large surface area, nanocarriers 
may interact with biomolecules such as peptides. Such 
interaction is a multifactorial process that depends on the 
properties of both, the peptide and the nanocarrier, and also 
on experimental conditions such as concentration and the 
medium.22,28 Both plectasin derivatives, AP114 and AP138, 
are peptides composed of 40 amino acids with very simi-
lar amino acid sequence and molecular weight (Table 1). 
They differ only by 3 amino acids (positions 9, 17, and 26 
from the amino end). The net charge at pH 7 is +3 and +4, 
and the theoretical isoelectric points are 8.62 and 8.87 for 
AP114 and AP138, respectively. The cationic property of 
the antimicrobial peptides is very important, because the 
electrostatic forces between the positively charged peptide 
and the negatively charged bacterial surface are critical 
determinants for their interactions, which is a key factor for 
antibacterial activity whether the membrane itself is targeted 
or when an intracellular target must be reached by means of 
translocation.29
It is very unlikely that the antimicrobial peptides showing 
good solubility in water, for example, plectasin derivatives, 
would penetrate into the oily core of the LNCs. Instead, they 
are expected to be localized within or on the particle shell.22 
The adsorption of the peptide did not cause an important 
change in the properties of the LNCs (Table 2). The size 
distribution remained unaffected, and the increase in the 
nanocapsule diameter, although statistically significant at the 
lowest LNC/peptide MMR, can be considered as negligible, 
because the difference in particle size was considerably small 
(1 nm). It is in agreement with previously reported data 
that the adsorption of peptide onto LNCs without ionizable 
surfactants did not change the properties of the nanocarrier.22 
The adsorption yield ranged from 34% to 62%. The per-
centage of adsorbed peptide increased corresponding to an 
increasing LNC/peptide MMR. AP114 and AP138 showed 
comparable adsorption yield, which can likely be attributed to 
their similar composition and physical properties. Although 
the interactions between the peptides and the nanocarriers 
are governed mainly by electrostatic forces,30,31 it is possible 
to achieve significant adsorption of peptide onto LNCs even 
without the presence of an ionizable surfactant because of 
the enormous surface area of the nanocarriers and of the 
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Figure 2 Flow curve of monolaurin-lipid nanocapsules.
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peptide–carrier interactions (such as dipol–ion interactions 
between the cationic groups of peptides and PEG dipoles on 
macrogol 15 hydroxystearate molecules).22 A peptide loading 
of 1.5% or even 2.7% can be considered as high for lipidic 
nanocarriers – they are usually characterized by smaller 
loading of molecules than the nanocarriers made of hydro-
philic polymers encapsulating the drug based on electrostatic 
interactions.30,31 The DL is a key parameter when developing 
an effective nanoparticulate delivery system, because low 
loading may limit the use of nanoparticulate systems because 
a substantial amount of the formulation must be administered 
to achieve the therapeutic effect.32
antibacterial properties of Ml-lNcs
The MICs of ML-LNCs against different strains of S. aureus 
are shown in Table 3. The MICs of ML-LNCs were 100 or 
200 or 400 µg/mL depending on the strain (corresponding 
to 15, 30, and 60 µg/mL of ML, respectively). MSSA strains 
seemed to be slightly more sensitive to ML-LNCs – five 
strains were inhibited by ML-LNCs at 100 µg/mL (15 µg/mL 
of ML), whereas among MRSA strains only one strain was 
inhibited by 100 µg/mL of ML-LNCs; most of the strains 
were inhibited by ML-LNCs at 200 µg/mL (30 µg/mL). 
The highest MIC (400 µg/mL of ML-LNCs, which contains 
60 µg/mL of monolaurin) was observed for MSSA.
Time-kill curves revealed that ML-LNCs were bacte-
ricidal (Figure 3). In the absence of ML-LNCs, bacterial 
counts reached their maximum 18–24 hours after inoculation. 
The killing was time dependent rather than concentration 
dependent. The killing occurred slowly – even at such a 
high concentration as 50 mg/mL (500× MIC) the reduction 
in the colony-forming unit (CFU) number after 3 hours was 
relatively small (~2 Log). This is in good agreement with 
the previously reported data.18
Because ML-LNCs were characterized by low killing 
rates even at very high concentrations (500× MIC), it can be 
concluded that they do not solubilize the bacterial membrane 
as do other detergents, including monoglycerides or fatty 
acids with shorter chains.18 It is very likely that monolaurin 
decreases the fluidity of the membrane, because it has a melt-
ing point of 63°C and, therefore, is solid at 37°C.18 This may 
modulate the activity of membrane proteins thereby playing 
an important role in cellular functions and homeostasis.33 
Monolaurin has been shown to inhibit the production of toxic 
shock syndrome toxin 1 and staphylococcal enterotoxins. 
The production of exotoxins by S. aureus was inhibited 
at monolaurin concentration that did not inhibit bacterial 
growth.14,17,34,35 Monolaurin has 12 carbon molecules in 
its fatty acid backbone chain, which makes it span exactly 
one-half the width of a lipid bilayer.36 Interestingly, it has 
Table 1 structure and properties of antimicrobial peptides
Peptide AP114 = NZ2114 AP138
sequence gFgcNgPWNeDDlrchNhcKsIKgYKggYc 
aKggFVcKcY
cyclic cys4–cys30, cys15–cys37, cys19–cys39
gFgcNgPWseDDlrchrhcKsIKgYrggYc 
aKggFVcKcY
cyclic cys4–cys30, cys15–cys37, cys19–cys39
Molecular weight 4,417 Da 4,460.3 Da
Theoretical pI 8.62 8.87
Number of amino acids 40 40
Number of cationic amino acids 6 7
Number of anionic amino acids 3 3
Net charge at ph 7 +3 +4
Note: The information was obtained from the manufacturer (aP114: adenium Biotech, Denmark; aP138: PolyPeptide laboratories, sweden).
Table 2 composition and properties of Ml-lNcs and peptide-loaded Ml-lNcs
Peptide LNC/peptide  
MMR
Adsorption  
efficiency (%)
Peptide  
loading (%)
Particle  
diameter (nm)
Polydispersity 
index
– N/a N/a N/a 36.0±0.30 0.026±0.020
aP138 100 61.96±0.94 0.6196±0.0094 36.2±0.18 0.024±0.009
aP138 50 46.15±0.62 0.9230±0.0125 36.4±0.13 0.037±0.017
aP138 25 37.39±0.81 1.4955±0.0322 36.8±0.17* 0.051±0.011
aP114 50 47.80±0.47 0.9560±0.0094 36.3±0.13 0.021±0.009
aP114 25 42.71±1.58 1.7802±0.0631 36.6±0.25 0.023±0.010
aP114 12.5 33.91±2.88 2.7130±0.2305 36.8±0.25* 0.036±0.011
Notes: Peptide concentration was 1,000 µg/ml. *P0.05 versus blank Ml-lNcs.
Abbreviations: MMr, mass mixing ratio; Ml-lNcs, monolaurin-lipid nanocapsules; N/a, not applicable.
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been reported that the optimum chain length of fatty acids 
and their corresponding monoglycerides to achieve the 
maximum antibacterial activity is 12 carbons.18,37,38 Because 
of its size and lipophilic nature, it has been postulated that 
glycerol monolaurate is inserted into cytoplasmic membrane 
and exerts its antibacterial effect by interfering with many 
transmembrane signal transduction systems.14,39
The influence of ML-LNCs on S. aureus morphology 
was studied by transmission electron microscopy (Figure 4). 
TE micrographs of control (untreated bacteria – Figure 4A) 
showed proliferating cells that were uniformly shaped 
with intact cell walls and well-defined cell membranes. 
In ML-LNC-treated cells, disappearance of plasma mem-
brane was observed (Figure 4B). ML-LNCs also exerted 
the effects on the cell wall – in some cells, the disappear-
ance of cell wall was observed. This is in agreement with 
the effects of monocaprin on group B streptococci observed 
by Bergsson et al.40 Interestingly, ML-LNCs affected the 
shape of bacteria – characteristic concave deformations were 
observed in numerous cells. Some lysed cells were observed 
with the leakage of cytoplasm contents. Proliferating cells 
were observed, therefore suggesting that ML-LNCs do not 
stop cell division, but numerous abnormalities described 
above occurred during cell division.
antibacterial activity of plectasin 
derivatives
The MICs of plectasin derivatives against 14 studied strains 
are shown in Table 3. The MICs of AP114 varied eightfold 
(range 1–8 µg/mL), whereas those of AP138 varied 16-fold 
(range 0.125–4 µg/mL). One of the MSSA strains was 
very sensitive to plectasin derivatives (MICs of 0.125 and 
1 µg/mL for AP138 and AP114, respectively). The existence 
of S. aureus mutants that are more sensitive to host defense 
peptides such as plectasin has been described previously.41 
It can be concluded that AP138 was more effective than 
AP114. Both plectasin derivatives effectively inhibited all 
tested strains of S. aureus, independent of their resistance 
pattern. This is in good agreement with the previously reported 
data indicating that the antibacterial spectrum of NZ2114 or 
AP138 includes staphylococci such as MRSA.7,9,13,42
Time-kill assay of plectasin derivatives was performed to 
determine the effect of an increasing peptide concentration 
on the extent of bacteria killing. Time-kill curves of ATCC 
25293 (MSSA) exposed to AP114 are shown in Figure 5A. 
In the presence of 1 or 2 µg/mL of AP114 (0.125× or 0.25× 
MIC, respectively), the bacterial counts grew more slowly 
than with the control. At 4 µg/mL (0.5× MIC), an evident 
growth inhibition was observed – the effect can be considered 
as bacteriostatic; however, after 18–24 hours of incubation, 
large standard deviations were observed and it was possible 
to observe visually slight bacterial growth. At 8 µg/mL of 
AP114 (1× MIC), a reduction by ~1.6 Log in the number of 
CFU was observed after 3 hours, 2.5 Log after 6 hours, and 
4.3 Log after 18 hours. At 16 µg/mL of AP114 (2× MIC), 
a dramatic reduction of bacterial density by 3.3 Log was 
observed after 3 hours, and the bactericidal effect was 
Table 3 MIcs of Ml-lNcs and plectasin derivatives against diffe-
rent Staphylococcus aureus isolates
Strain Strain ID MIC AP114 MIC AP138 MIC ML-LNCs
Mrsa 0706c0025 4 2 200
Mrsa 11004533801 4 2 200
Mrsa 11004691801 4 2 200
Mrsa 11004787401 8 2 100
Mrsa 11006153901 8 4 200
Mrsa 070170095 4 2 200
Mrsa 0702e0196 4 2 200
Mssa 11004327701 1 0.125 100
Mssa 11004480701 8 2 400
Mssa 11004697301 4 1 100
Mssa 11004010401 4 2 100
Mssa 0703h0036 4 1 100
Mssa 0701a0095 4 2 200
Mssa aTcc 25923 8 4 100
Notes: MIcs are expressed in µg/ml. Ml-lNcs contain 15% of monolaurin.
Abbreviations: MIcs, minimum inhibitory concentrations; Ml-lNc, monolaurin-
lipid nanocapsules; Mrsa, methicillin-resistant Staphylococcus aureus; Mssa, methicillin-
susceptible Staphylococcus aureus.
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Figure 3 Time-kill curves of Ml-lNcs against Mssa aTcc strain.
Abbreviations: Ml-lNcs, monolaurin-lipid nanocapsules; Mssa, methicillin-
susceptible Staphylococcus aureus.
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Figure 4 Transmission electron microscope images of Mssa aTcc strain untreated control (A) and treated with 3.2 mg/ml (32× MIc) of Ml-lNcs (B) for 1 hour. scale 
bars: (A) left: 0.2 µm, right: 0.2 µm; (B) left: 0.5 µm, right: 100 nm.
Abbreviations: MIc, minimum inhibitory concentration; Ml-lNcs, monolaurin-lipid nanocapsules; Mssa, methicillin-susceptible Staphylococcus aureus.
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Figure 5 Time-kill curves of plectasin derivatives aP114 (A) and aP138 (B) against Mssa aTcc 25923 strain. The MIc values were 8 and 4 µg/ml for aP114 and aP138, 
respectively.
Abbreviations: MIc, minimum inhibitory concentration; Mssa, methicillin-susceptible Staphylococcus aureus.
maintained for at least 24 hours. Time-kill curves of ATCC 
25293 (MSSA) exposed to AP138 are shown in Figure 5B. 
At 1 µg/mL of AP138 (0.25× MIC), the bacterial count grew 
more slowly than that of control. At 2 µg/mL (0.5× MIC), 
an inhibition of bacterial growth was observed; the effect 
can be considered as bacteriostatic with the increase in 
the number of CFU by 1 Log compared with the initial 
inoculum. At 4 µg/mL (1× MIC), a gradual decrease in the 
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CFU number by 2.3 was observed within 24 hours – at this 
concentration, the action can be considered as bacteriostatic. 
At 8 and 16 µg/mL (2× and 4× MIC, respectively), a reduc-
tion by 1.5 Log was observed after 3 hours, by 2.3–2.7 Log 
after 6 hours, and the bactericidal effect was reached after 
18 hours. Time-kill results confirmed that AP138 was more 
potent than AP114. However, AP114 killed bacteria more 
rapidly than AP138. At 16 µg/mL, the bactericidal effect, 
that is, a reduction of more than 3 Log in CFU number com-
pared with the starting inoculum, was observed after 3 hours 
for AP114, whereas AP138 was not bactericidal even after 
6 hours of incubation.
Although many antimicrobial peptides act on and disinte-
grate bacterial cytoplasmic membrane, this is not the case for 
plectasin. In spite of its amphipathic structure, this peptide 
does not compromise membrane integrity, thereby reducing 
the risk of unspecific toxicity.7 Indeed, AP114 (NZ2114) 
showed very low hemolytic activity (0.1% of hemolysis 
at 128 µg/mL).42 Another study has confirmed that plectasin 
is neither hemolytic for human erythrocytes (half maximal 
effective concentration [EC
50
] 400 µg/mL) nor cytotoxic 
for human epidermal keratinocytes (EC
50
 400 µg/mL) or 
for murine L929 fibroblasts (EC
50
 400 µg/mL).6 Plecta-
sin and its derivatives exhibit their antibacterial activity 
by interfering with cell wall biosynthesis. These peptides 
directly bind to bacterial cell wall precursor lipid II form-
ing an equimolar stoichiometric complex.7 It has been 
demonstrated that AP114 shows bactericidal mode of 
action, with the MBC/MIC ratios ranging from 1 to 2 for 
either MSSA or MRSA strains.41,42 These results are in a 
good agreement with our time-kill data. Time-kill studies of 
plectasin performed by Schneider et al7 demonstrated that 
the time-kill behavior of plectasin was similar to that of 
agents interfering with cell wall synthesis (such as vancomy-
cin or penicillin). Plectasin did not exhibit similar time-kill 
profile characteristic as the rapidly lytic membrane-active 
agents such as polymyxin B.7
Figure 6 shows influence of AP114 (Figure 6A) and AP138 
(Figure 6B) on the morphology of S. aureus. Incubation 
with plectasin derivatives resulted in a destruction of 
cell walls. It was possible to observe cell walls that have 
separated from the cells, disappearance of fragments of cell 
membrane, and the leakage of cytoplasmic contents. Shape 
deformations and abnormalities in shape division were also 
observed. These observations are in agreement with the fact 
that plectasin derivatives exert their antibacterial effect by 
interfering with cell wall synthesis.
synergistic interactions between plectasin 
derivatives and Ml-lNcs
Combinations containing a plectasin derivative and the 
ML-LNCs were tested on one MSSA reference strain and 
one MRSA strain to evaluate whether they can still enhance 
SA killing. The efficacies of these combinations were 
Figure 6 Transmission electron microscope images of Mssa aTcc 25923 strain treated with 128 µg/ml (32× MIc) of aP114 (A) and 64 µg/ml (32× MIc) of aP138 
(B) for 1 hour. scale bars: (A) left: 0.2 µm, right: 100 nm; (B) left: 0.2 µm, right: 200 nm.
Abbreviations: MIc, minimum inhibitory concentration; Mssa, methicillin-susceptible Staphylococcus aureus.
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assessed using checkerboard method and time-kill assay. 
The antibacterial activity of peptide-loaded ML-LNCs was 
the same as the activity of combinations containing the same 
concentrations of ML-LNCs and a plectasin derivative that 
were prepared by mixing of the components in the 96-well 
plate just before the addition of bacteria (not shown). In the 
checkerboard method, the values of FIC index were equal 
to 0.375 or 0.5, indicating synergistic interactions between 
each plectasin derivative (AP114 or AP138) and ML-LNCs 
against both MSSA and MRSA strains (Table 4). By using 
the combinations, it was possible to reduce the concentrations 
of both, peptide and LNCs, fourfold.
Time-kill study showed that none of the ingredients 
used alone was capable of effectively inhibiting bacterial 
growth at tested concentrations (Figure 7). The combina-
tion of ML-LNCs at 25 µg/mL and AP114 at 1 µg/mL can 
be considered as synergistic (the CFU number was ~3 Log 
smaller than that of each of ingredients alone), but after 
24 hours an increase in CFU number by 1.2 Log was observed 
compared with the initial inoculum (Figure 7A). An increase 
in the concentration of either AP114 or ML-LNCs or both 
of them yielded synergistic and bactericidal combinations. 
The reduction in CFU number was gradual (after 6 hours 
only the combination containing AP114 2 µg/mL and 
ML-LNCs 50 µg/mL proved to be bactericidal). The com-
binations showed at least an 8 Log reduction in the CFU 
number compared with the ingredients alone after 24 hours 
of incubation.
All tested combinations containing AP138 and ML-LNCs 
showed synergistic effects (Figure 7B). Both samples 
containing 0.5 µg/mL AP138 reduced the CFU number by 
2.1 Log after 3 hours and 2.6–2.8 Log after 6 hours. The 
samples containing more AP138 (1 µg/mL) showed larger 
reductions in CFU number: by 2.6–2.7 Log after 3 hours 
and after 6 hours they showed bactericidal effect reducing 
CFU number by 3.6–3.9 Log. All combinations showed 
bactericidal effect after 18 and 24 hours with at least an 
8 Log reduction in the CFU number compared with the 
ingredients alone.
Figure 8 shows influence of synergistic combinations 
containing ML-LNCs and AP114 (Figure 8A) or AP138 
(Figure 8B) on S. aureus morphology. The changes described 
for ML-LNCs and the plectasin derivatives were also 
observed in their combinations. These include deformations 
in shape of bacterial cells, disappearance of cell walls and 
cell membranes, fragments of cell walls that have separated 
from bacterial cells, and leakage of cytoplasmic contents 
from the cells.
Both plectasin derivatives have been shown to act in syn-
ergy with ML-LNCs against S. aureus. A synergistic effect can 
result from a variety of mechanisms. Synergistic antibacterial 
effect is often observed when between the compounds that 
attack different targets. A possible explanation of synergistic 
effect between ML-LNCs and plectasin derivatives is that the 
peptides damage cell wall sufficiently to enhance the entry 
of ML and/or ML-LNCs. Indeed, inhibitors of cell wall syn-
thesis, for example, penicillin, show synergistic interactions 
with some antibiotics (eg, gentamicin) against enterococci by 
facilitating their entry as a result of cell wall damage.1
Antimicrobial peptides represent one of the most prom-
ising and innovative groups of anti-infective agents.6,29,41 
The in vitro emergence of resistance to antimicrobial 
peptides is less common and less rapid than that observed 
for conventional antibiotics.43,44 More recently, however, 
a number of resistance mechanisms against antimicrobial 
peptides have been discovered and investigated in bacteria. 
The examples of such mechanisms include the release of 
glycosaminoglycans and other polyanionic molecules to 
scavenge positively charged peptides or membrane modifi-
cation resulting in a decrease of negative surface potential 
of bacterial membranes.45–47 The latter mechanisms have 
been described for S. aureus.48 On the other hand, it has 
been demonstrated that the resistance to monolaurin does 
not develop even after a year of passaging of S. aureus 
on media containing a subinhibitory concentration of this 
compound.14,17 Moreover, it has been shown that glycerol 
monolaurate inhibits the induction of resistance to vanco-
mycin in Enterococcus faecalis.49 In conclusion, combined 
Table 4 MIcs of Ml-lNcs and plectasin derivatives used alone and in combination against Mssa and Mrsa
Strain Peptide MIC of peptide  
alone
MIC of peptide  
in mixture
MIN of ML-LNCs  
alone
MIC of ML-LNCs  
in mixture
FIC 
index
Mrsa 0702e0196 aP138 2 0.5 200 25 0.375
Mrsa 0702e0196 aP114 4 1 200 50 0.5
Mssa aTcc 25923 aP138 4 1 100 25 0.5
Mssa aTcc 25923 aP114 8 2 100 25 0.5
Note: MIcs are expressed in µg/ml.
Abbreviations: FIc, fractional inhibitory concentration; MIcs, minimum inhibitory concentrations; Mrsa, methicillin-resistant Staphylococcus aureus; Mssa, methicillin-
susceptible Staphylococcus aureus.
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Figure 7 Time-kill curves of Ml-lNcs and plectasin derivatives aP114 (A) and aP138 (B) used alone and in combination against Mssa aTcc strain.
Abbreviations: Ml-lNcs, monolaurin-lipid nanocapsules; Mssa, methicillin-susceptible Staphylococcus aureus.
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Figure 8 Transmission electron microscope images of Mssa aTcc strain treated with containing 1.6 mg/ml of Ml-lNcs and plectasin derivative: 64 µg/ml of aP114 (A) 
or 32 µg/ml of aP138 for 1 hour. scale bars: (A) left: 0.2 µm, right: 0.2 µm; (B) left: 0.5 µm, right: 0.2 µm.
Abbreviations: Ml-lNcs, monolaurin-lipid nanocapsules; Mssa, methicillin-susceptible Staphylococcus aureus.
administration of ML-LNCs and plectasin derivatives could 
markedly decrease the probability of development of resis-
tance to the latter. Therefore, ML-LNCs can be considered 
as a very promising carrier for plectasin derivatives and pos-
sibly for other antimicrobial peptides.
Conclusion
Several interesting findings emerged from the present study. 
First, plectasin derivatives were adsorbed on the LNCs with 
the efficiency between 34% and 62% without having an 
important impact on the nanocarrier properties such as size. 
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Second, when used alone, ML-LNCs and both plectasin 
derivatives were effective against all tested MSSA and 
MRSA strains with the MIC values of 100–400 µg/mL and 
0.125–8 µg/mL for the nanocarriers and peptides, respec-
tively. Both the peptides and the ML-LNCs showed bacteri-
cidal activity. Third, when used in combination, synergistic 
effect was observed between plectasin derivatives and ML-
LNCs as confirmed by both, checkerboard and time-kill assay. 
This enables the dose reduction and consequently decreases 
the risk of toxic effects and minimizes the possibility of 
resistance development. Together, these results suggest that 
ML-LNCs loaded with a plectasin derivative may be a very 
promising drug delivery system for further development as a 
novel antibacterial agent against MRSA and MSSA.
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